卡瑞利珠单抗联合顺铂化疗对晚期非小细胞肺癌患者血清肿瘤标志物水平、免疫功能的影响  

Effects of carrellizumab combined with cisplatin chemotherapy on serum tumor marker levels and immune function in patients with advanced non-small cell lung cancer

作　　者：侯梦林 Hou Menglin(Navy 971 Hospital,Qingdao,Shandong 266071,China)

机构地区：[1]中国人民解放军海军第971医院,山东青岛266071

出　　处：《首都食品与医药》2024年第23期76-78,共3页Capital Food Medicine

摘　　要：目的 分析卡瑞利珠单抗联合顺铂化疗对晚期非小细胞肺癌(NSCLC)患者血清肿瘤标志物水平、免疫功能的影响.方法 选择海军971医院2019年1月-2023年12月收治的60例晚期NSCLC患者为研究对象,按照随机对照原则分为联合组(卡瑞利珠单抗联合顺铂)和对照组(顺铂),每组30例,比较两组疗效、不良反应及治疗前后血清肿瘤标志物水平(CYFRA21-1、CA125、CEA)、免疫功能(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)).结果 与对照组比较,联合组疾病控制率、客观缓解率更高(P<0.05).治疗前,两组CYFRA21-1、CA125、CEA、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比较,无统计学差异(P>0.05);治疗后,与对照组比较,联合组CYFRA21-1、CA125、CEA、CD8^(+)更低(P<0.05),CD4^(+)、CD4^(+)/CD8^(+)更高(P<0.05).两组不良反应发生率比较,无统计学差异(P>0.05).结论 采用卡瑞利珠单抗联合顺铂治疗晚期NSCLC患者,可取得较为满意的疗效,降低血清肿瘤标志物水平,改善免疫功能,且安全性较高.Objective To analyze the effects of carrilizumab combined with cisplatin chemotherapy on serum tumor marker levels and immune function in patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 60 patients with advanced NSCLC admitted to Navy 971 Hospital from January 2019 to December 2023 were selected as the study objects,and were divided into a combination group(carrilizumab combined with cisplatin)and a control group(cisplatin)according to the randomized control principle,with 30 cases in each group.The efficacy,adverse reactions,serum tumor marker levels(CYFRA21-1,CA125,CEA)and immune function(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))were compared between the two groups.Results Compared with control group,the disease control rate and objective remission rate of combination group were higher(P<0.05).Before treatment,there were no significant differences in CYFRA21-1,CA125,CEA,CD4^(+),CD8^(+),CD4^(+)/CD8^(+)between the two groups(P>0.05).After treatment,compared with control group,CYFRA21-1,CA125,CEA and CD8^(+)in combination group were lower(P<0.05),and CD4^(+),CD4^(+)/CD8^(+)were higher(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Carrellizumab combined with cisplatin in the treatment of advanced NSCLC patients can achieve satisfactory efficacy,reduce the level of serum tumor markers,improve immune function,and have high safety.

关 键 词：卡瑞利珠单抗 晚期非小细胞肺癌 疗效 血清肿瘤标志物水平 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]